Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Up 387.7% in July

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 17,416 shares, a growth of 387.7% from the July 15th total of 3,571 shares. Based on an average daily trading volume, of 77,992 shares, the short-interest ratio is presently 0.2 days. Approximately 1.9% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Cuprina Holdings (Cayman) from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cuprina Holdings (Cayman) presently has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Price Performance

CUPR traded down $0.06 during trading on Friday, hitting $3.04. 24,046 shares of the company’s stock were exchanged, compared to its average volume of 1,366,313. Cuprina Holdings has a 1 year low of $1.76 and a 1 year high of $76.00. The stock has a 50 day moving average price of $4.12 and a 200 day moving average price of $3.29. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.35 and a quick ratio of 2.35.

Institutional Trading of Cuprina Holdings (Cayman)

An institutional investor recently bought a new stake in Cuprina Holdings (Cayman) stock. Manning & Napier Advisors LLC bought a new position in Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,630,867 shares of the company’s stock, valued at approximately $168,748,000. Cuprina Holdings (Cayman) accounts for 2.2% of Manning & Napier Advisors LLC’s holdings, making the stock its 15th largest holding. Manning & Napier Advisors LLC owned approximately 1,372.92% of Cuprina Holdings (Cayman) as of its most recent SEC filing.

About Cuprina Holdings (Cayman)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.